Catalyst Funds Management Pty LTD Akero Therapeutics, Inc. Transaction History
Catalyst Funds Management Pty LTD
- $455 Billion
- Q3 2024
A detailed history of Catalyst Funds Management Pty LTD transactions in Akero Therapeutics, Inc. stock. As of the latest transaction made, Catalyst Funds Management Pty LTD holds 800 shares of AKRO stock, worth $23,384. This represents 0.01% of its overall portfolio holdings.
Number of Shares
800Holding current value
$23,384% of portfolio
0.01%Shares
1 transactions
Others Institutions Holding AKRO
# of Institutions
190Shares Held
73.8MCall Options Held
241KPut Options Held
647K-
Wellington Management Group LLP Boston, MA7.9MShares$231 Million0.04% of portfolio
-
Janus Henderson Group PLC London, X07.08MShares$207 Million0.11% of portfolio
-
Rtw Investments, LP New York, NY5.92MShares$173 Million2.71% of portfolio
-
Black Rock Inc. New York, NY5.59MShares$163 Million0.0% of portfolio
-
General Atlantic LLC New York, NY5.23MShares$153 Million4.29% of portfolio
About Akero Therapeutics, Inc.
- Ticker AKRO
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 46,417,600
- Market Cap $1.36B
- Description
- Akero Therapeutics, Inc., a cardio-metabolic nonalcoholic steatohepatitis (NASH) company, engages in the development of medicines designed to restore metabolic balance and improve overall health. The company's lead product candidate is efruxifermin (EFX), an analog of fibroblast growth factor 21, which protects against cellular stress and regula...